-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Good News! Shijiazhuang Sihua Pharmaceutical Has Been Recognized as a National Quality Benchmark Enterprise
Category:
发布时间：2023-11-24
【概要描述】
On November 23, the China Association for Quality issued the “Notice on Announcing the Results of the Selection of Typical National Quality Benchmark Experiences for 2023,” under which Shijiazhuang Sihua Pharmaceutical Co., Ltd. was successfully recognized as a 2023 National Quality Benchmark Enterprise.
On November 23, the China Association for Quality issued the “Notice on Announcing the Results of the Selection of Typical Best Practices for National Quality Benchmarks in 2023,” under which Shijiazhuang Sihua Pharmaceutical Co., Ltd. was successfully recognized as a 2023 National Quality Benchmark Enterprise.
The National Quality Benchmark is a national-level honor initiated by the Ministry of Industry and Information Technology and organized by the China Association for Quality, aimed at strengthening and elevating enterprises’ quality management capabilities and fostering the development of world-class companies that excel in product quality, brand reputation, innovation leadership, modern governance, and core competitiveness. The 2023 National Quality Benchmark selection focused primarily on upgrading quality management systems, controlling quality in key processes, enhancing the resilience and security of industrial and supply chains, and advancing the digital transformation of quality management. This year, a total of 69 enterprises had their quality management practices recognized as National Quality Benchmarks. Shijiazhuang Sihua Pharmaceutical’s submission, “Experience in Ensuring Pharmaceutical Quality and Safety through the ‘21235’ Risk Management Model Based on Parameter-Based Release,” was selected as a model practice in the category of key process quality control.
As a key pillar enterprise in our city’s biopharmaceutical industry, Shijiazhuang No. 4 Pharmaceutical has long upheld the principle of putting people and life first, regarding the research, development, and production of high-quality “Made-in-China” medicines as its core mission. The company actively benchmarks against internationally advanced quality management concepts and systems, and in the manufacturing of its flagship infusion preparations, has proactively explored and established a “21235” risk-control model based on parameter-based release: creating two sets of standards, employing one tool, solidifying two safeguards, strengthening three supports, and optimizing five processes. By leveraging automated, information-driven, and intelligent quality-management approaches, the company has achieved high-level, integrated, closed-loop quality management across the entire value chain—from R&D to production—while continuously improving its quality-management system, fostering synergistic development between quality management and technological innovation, accelerating the move of its products and industries toward the high end of the value chain, constantly enhancing its core competitiveness, and serving as a model and driver for the industry’s high-quality development.
The group’s principal stated that, as a new starting point following its recognition as a national quality benchmark, the next step will be to continuously implement the strategy of building a quality-driven enterprise, further establish and improve the quality management system and technical standards framework, refine the quality assessment and evaluation mechanism, consolidate the quality foundation, leverage the leading and exemplary role, and thereby boost the enterprise’s quality management capabilities and achieve new breakthroughs in innovative, high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091